ATCC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ATCC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011832
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ATCC is a nonprofit bioresource center and research organization that provides biological products, technical services and educational programs. The organization acquires, preserves, develops, authenticates, produces, and distributes standard reference microorganisms, cell lines and other materials. Its products include nucleic acids, cells and microorganisms, testing and characterization, cells extracts, culture reagents, quality control strains, proteins and cell extracts. ATCC’s services include production and characterization, biorepository management, testing services, and deposit services. The organization offers custom testing services for mycoplasma detection and human cell line authentication. It serves research and life science industry. The organization also provides storage of biomaterials through its facility. ATCC is headquartered in Manassas, Virginia, the US.

ATCC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ATCC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ATCC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ATCC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ATCC, Medical Devices Deals, 2011 to YTD 2017 8
ATCC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ATCC, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Horizon Discovery Enters Into Licensing Agreement With ATCC 10
ATCC Forms Joint Venture with ILSE 11
BioCision Enters Into Co-Development Agreement With ATCC 12
Promega Enters Into An Agreement With ATCC 13
ATCC Enters Into Co-Development Agreement With Stemgent 14
Licensing Agreements 15
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 15
Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 16
ATCC Enters into Licensing Agreement with Baylor College of Medicine 17
ATCC Enters Into Licensing Agreement With Life Technologies For GFP Technology 18
ATCC Enters Into Licensing Agreement With iPS Academia Japan 19
ATCC – Key Competitors 20
ATCC – Key Employees 21
ATCC – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 22
Recent Developments 23
Strategy And Business Planning 23
Apr 21, 2017: ATCC Opens Doors to New High-Tech Biorepository in Gaithersburg, MD 23
Corporate Communications 24
May 12, 2016: ATCC Names Dr. Mindy Goldsborough As Chief Science And Technology Officer 24
Product News 25
Nov 20, 2017: ATCC develops novel in vitro model to investigate drug candidates for cancer metastasis 25
Apr 21, 2016: ATCC Launches Custom Cell Lines Funded By The Michael J. Fox Foundation For Parkinson’S Research 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
ATCC, Pharmaceuticals & Healthcare, Key Facts 2
ATCC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
ATCC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ATCC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ATCC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ATCC, Medical Devices Deals, 2011 to YTD 2017 8
ATCC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Horizon Discovery Enters Into Licensing Agreement With ATCC 10
ATCC Forms Joint Venture with ILSE 11
BioCision Enters Into Co-Development Agreement With ATCC 12
Promega Enters Into An Agreement With ATCC 13
ATCC Enters Into Co-Development Agreement With Stemgent 14
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 15
Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 16
ATCC Enters into Licensing Agreement with Baylor College of Medicine 17
ATCC Enters Into Licensing Agreement With Life Technologies For GFP Technology 18
ATCC Enters Into Licensing Agreement With iPS Academia Japan 19
ATCC, Key Competitors 20
ATCC, Key Employees 21
ATCC, Joint Venture 22

★海外企業調査レポート[ATCC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HTC Corporation:戦略・SWOT・企業財務分析
    HTC Corporation - Strategy, SWOT and Corporate Finance Report Summary HTC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Texas A&M University-製薬・医療分野:企業M&A・提携分析
    Summary Texas A&M University (TAMU) is a research based university that offers educational and research services. The university provides undergraduate, graduate and professional courses to its students. It consists of various colleges and departments such as College of Agriculture and Life Sciences …
  • Empire Energy Group Ltd (EEG):石油・ガス:M&Aディール及び事業提携情報
    Summary Empire Energy Group Ltd (EEGL), formerly Imperial Corp Ltd is an oil and gas company that offers exploration and production programs. The company produces and develops oil and gas assets; and has interest in onshore oil and gas fields in Mid Con property and Appalachia property. It has onsho …
  • AptarGroup Inc:企業の戦略・SWOT・財務分析
    AptarGroup Inc - Strategy, SWOT and Corporate Finance Report Summary AptarGroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • InSphero AG:製薬・医療:M&Aディール及び事業提携情報
    Summary InSphero AG (InSphero) is a biotechnology company that offers production, culture and assessment of organotypic 3D cell culture models. The company’s product portfolio includes microtissues kits, cytotoxicity assay kits, and microtissue spheroids, among others. Its patented 3D cell culture p …
  • Mayo Foundation for Medical Education and Research:企業の戦略的SWOT分析
    Mayo Foundation for Medical Education and Research - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compet …
  • UNIQA Serbia:企業の戦略・SWOT・財務情報
    UNIQA Serbia - Strategy, SWOT and Corporate Finance Report Summary UNIQA Serbia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Blaze Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Blaze Bioscience Inc (Blaze) is a biotechnology company that offers guided cancer therapy solutions. The company develops tumor paint products and optide-based guided cancer therapeutics. It provides cancer surgery by development of real-time, high-resolution view of cancer cell technologies …
  • Compugen Ltd (CGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Compugen Ltd (Compugen) is a drug discovery company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises CGEN-15001T, CGEN-15022, CGEN-15022, CGEN-15029, target candidates, immuno-modulatory target candidates and ADC target can …
  • Dassault Aviation SA (AM):企業の財務・戦略的SWOT分析
    Dassault Aviation SA (AM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Medicure Inc (MPH):企業の財務・戦略的SWOT分析
    Summary Medicure Inc (Medicure) is a pharmaceutical company that strives to research, develop and commercialize therapeutics for cardiovascular diseases. The company’s product portfolio comprises Aggrastat, a glycoprotein GP IIb/IIIa receptor antagonist indicated for the treatment of acute coronary …
  • Leidos Holdings Inc:企業のM&A・事業提携・投資動向
    Leidos Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Leidos Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Dunkin’ Brands Group Inc:企業の戦略・SWOT・財務情報
    Dunkin' Brands Group Inc - Strategy, SWOT and Corporate Finance Report Summary Dunkin' Brands Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Anadarko Petroleum Corp (APC):企業の財務・戦略的SWOT分析
    Anadarko Petroleum Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Air Liquide SA (AI)-エネルギー分野:企業M&A・提携分析
    Summary Air Liquide SA (Air Liquide) is a provider of gases, technologies and services for industry and health. The company produces core air gases such as oxygen, nitrogen, and hydrogen along with argon and other rare gases. It supplies gases to customers in multiple industries, including steel, ch …
  • DEME NV:企業の戦略的SWOT分析
    DEME NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Finmeccanica SpA:戦略・SWOT・企業財務分析
    Finmeccanica SpA - Strategy, SWOT and Corporate Finance Report Summary Finmeccanica SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Midsona AB (MSON B):企業の財務・戦略的SWOT分析
    Summary Midsona AB (Midsona), formerly Midelfart Sonesson AB is a healthcare products manufacturing company that provides personal care products, health foods, and hygiene products. The company’s products include superfood, sports nutrition, dietary supplements, nutritional supplements, organic food …
  • Ingredion Incorporated:企業の戦略・SWOT・財務情報
    Ingredion Incorporated - Strategy, SWOT and Corporate Finance Report Summary Ingredion Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • iPass Inc. (IPAS):企業の財務・戦略的SWOT分析
    iPass Inc. (IPAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆